{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:50:45Z","timestamp":1788263445909,"version":"build-2803163510"},"reference-count":9,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Daratumumab is a monoclonal antibody targeting CD38 and is widely used in the treatment of multiple myeloma. While generally well tolerated, pulmonary toxicity is a rare and under-recognised adverse effect. We present the case of an elderly woman with multiple myeloma on maintenance daratumumab therapy who developed subacute hypoxic respiratory failure. Imaging revealed new-onset diffuse bilateral ground-glass opacities. Bronchoscopy with lavage was non-diagnostic. Extensive infectious and rheumatologic workup was unrevealing. The patient improved significantly with corticosteroids and discontinuation of daratumumab, supporting a diagnosis of drug-induced pneumonitis. This case highlights the importance of considering monoclonal antibody-induced lung injury in the differential diagnosis of respiratory symptoms in patients receiving long-term CD38-directed therapy.<\/jats:p>","DOI":"10.1136\/bcr-2025-267801","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:25:20Z","timestamp":1758515120000},"page":"e267801","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Acute interstitial pneumonitis associated with daratumumab treatment"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-2195","authenticated-orcid":false,"given":"Navroop","family":"Momi","sequence":"first","affiliation":[{"name":"Family Medicine, Onvida Health, Yuma, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5068-8999","authenticated-orcid":false,"given":"Vaiishnavi","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Family Medicine, Onvida Health, Yuma, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Kumar Vasudevan","sequence":"additional","affiliation":[{"name":"Critical Care, Yuma Regional Medical Center, Yuma, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulothungan","family":"Gunasekaran","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care, Onvida Health, Yuma, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,21]]},"reference":[{"key":"2025092121251350000_18.9.e267801.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1790"},{"key":"2025092121251350000_18.9.e267801.2","first-page":"262","article-title":"Pulmonary side effects of drugs: a comprehensive review","volume":"19","author":"Cottin","year":"2010","journal-title":"Eur Respir Rev"},{"key":"2025092121251350000_18.9.e267801.3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7100356","article-title":"Drug-Induced Interstitial Lung Disease: A Systematic Review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"2025092121251350000_18.9.e267801.4","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1891","article-title":"Respiratory Complications in Multiple Myeloma: A Case of Pneumonitis Induced by Daratumumab","volume":"211","author":"Momi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2025092121251350000_18.9.e267801.5","doi-asserted-by":"crossref","first-page":"A3163","DOI":"10.1016\/j.chest.2023.07.2075","article-title":"DARATUMUMAB-INDUCED INTERSTITIAL LUNG DISEASE: A CASE REPORT","volume":"164","author":"Nothem","year":"2023","journal-title":"Chest"},{"key":"2025092121251350000_18.9.e267801.6","first-page":"541","article-title":"Interstitial pneumonitis associated with daratumumab: a case report","volume":"112","author":"Umeda","year":"2020","journal-title":"Int J Hematol"},{"key":"2025092121251350000_18.9.e267801.7","first-page":"1237","article-title":"Acute pneumonitis following daratumumab: A rare complication","volume":"27","author":"Katayama","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2025092121251350000_18.9.e267801.8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1111\/jcpt.13819","article-title":"Severe lung injury induced by CD38 monoclonal antibody Daratumumab and bortezomib-containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review","volume":"47","author":"Chen","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2025092121251350000_18.9.e267801.9","doi-asserted-by":"crossref","DOI":"10.1186\/2213-0802-2-4","article-title":"Diagnosis and management of interstitial lung disease","volume":"2","author":"Meyer","year":"2014","journal-title":"Transl Respir Med"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-267801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:25:21Z","timestamp":1758515121000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-267801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":9,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,21]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bcr-2025-267801"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-267801","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}